FDA 483 - Quagen Pharma, LLC - November 08, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Quagen Pharma, LLC in West Caldwell, NJ, was inspected for a Pre-Approval Inspection (PAI) related to Cyproheptadine Hydrochloride Tablets, USP 4mg. The inspection revealed significant deficiencies in quality control, including inadequate Out of Specification (OOS) investigations, insufficient cleaning validation procedures for equipment, and a failure of the quality unit to ensure comprehensive employee training on critical Standard Operating Procedures. These issues indicate a lack of robust quality systems and control over manufacturing processes.
ID · 69acecaa-79d7-4f23-a6f5-9cde9c82fa62